Atara Biotherapeutics, Inc.
ATRA
$10.51
$0.292.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -110.91% | 73.17% | 80.36% | 112.53% | 219.71% |
| Total Depreciation and Amortization | -98.38% | -4.64% | -178.37% | -82.26% | 29.04% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -87.32% | -114.34% | -66.85% | -72.94% | 13.52% |
| Change in Net Operating Assets | 99.08% | 91.19% | -220.04% | -277.51% | -599.85% |
| Cash from Operations | 89.08% | 76.72% | -145.35% | 31.25% | 4.98% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 127.50% | 85.21% | -175.00% | 15.86% |
| Cash from Investing | -- | 150.00% | 85.47% | -170.46% | 16.86% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | 100.00% | 100.00% | -10.13% |
| Issuance of Common Stock | -- | -70.74% | -- | -98.92% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 70.79% | -101.28% | 8,416.85% | -- |
| Cash from Financing | 1,280.40% | 99.09% | -97.07% | 4,823.46% | -101.04% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 98.91% | 112.79% | -173.72% | 177.29% | -221.01% |